Abstracts

SAFETY OF Ad26.COV2.S AND AZD1222 COVID-19 VACCINES AMONG ADULTS IN MALAWI

Background: The safety profiles of the Ad26.COV2.S and AZD1222 COVID-19 vaccines have not been described in a general population in Malawi. We present self-reported adverse reactions (AE) following receipt of these vaccines in Malawi as part of a phone-based syndromic surveillance survey. Methods: We conducted phone-based syndromic surveillance surveys among adults (≥18 years) with verbal…

MODELLING THE RISK OF FUTURE MPOX OUTBREAKS IN THE NETHERLANDS

Background: Outbreaks typically occur when a pathogen is introduced into a population with little or no immunity. The 2022 mpox outbreak among men-who-have-sex-with-men (MSM) was a good example. In the Netherlands, smallpox vaccination ended in 1974. During summer of 2022, MSM who engage in high-risk sexual behavior were offered vaccination with the Imvanex vaccine. In…

INNATE IMMUNITY IN HTLV-1 INFECTION: IFN-GAMMA LEVELS ARE UP-REGULATED IN EARLY HAM

Background: HTLV-1 infection is responsible for two aggressive diseases, leukemia and neuronal inflammation (HAM), in 5-10% of the chronically-infected asymptomatic carriers (AC). However, some infected individuals present minor symptoms that do not meet the criteria for HAM, while not asymptomatic which we named Intermediate syndrome (IS). To determine whether immune responses could discriminate IS from…

CONTROVERSIES IN HEPATITIS B

This presentation will focus on three controversies in hepatitis B treatment in people living with and without HIV infection. Controversies discussed include discontinuing nucleoside analogue therapy, screening for HCC with long-term suppression of HBV DNA on nucelos(t)ide analogue therapy, and treatment of immunotolerant chronic hepatitis B. The most recent data on these controversies will be…

THE ORIGINAL DELTA VIRUS OR D LIKE THE DEVIL

Hepatitis D or delta virus (HDV) is an ‘original’ RNA virus that requires the hepatitis B surface antigen (HBsAg) of hepatitis B virus (HBV) for transmission. The worldwide prevalence of HDV infection is difficult to classify. Recently, several systematic reviews have been published on this topic, reporting a worldwide prevalence of between 12 and 70…

STUDYING COVID TREATMENT OUTCOMES: WHY DISPARATE RESULTS?

Research during the Covid-19 outbreak has followed a pattern – observational data and case series followed by more rigorous randomized-controlled trials. The results of these trials have sometimes been inconsistent. Disparate results have arisen from small sample sizes, small changes in protocols and relatively small effect sizes. These issues can affect any clinical trial but…

ANALYSIS APPROACHES TO CORRELATES OF VACCINE EFFICACY

Vaccines are approved by regulatory agencies based on randomized, placebo-controlled vaccine efficacy (VE) trials that demonstrate vaccination is safe and reduces the risk of acquisition of an infectious disease clinical endpoint. The resource-intensity of VE trials make it difficult to base vaccine approval on this gold-standard approach for every indication of interest (defined by host…